Meanwhile, the median tumor-free survival rate in ERβ positive expression patients was 7.850 years, significantly lower than that in low ERβ expression patients (Log-rank test, χ2 = 10.748, P < 0.01). The gene discussed is ESR2; the disease is neoplasm.